Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.

Monitoring your response to chronic myeloid leukaemia (CML) treatment The aim of treatment is to put your chronic myeloid leukaemia (CML) into remission. Remission means there are no signs of CML in ...

On Monday, Tempus AI Inc. (NASDAQ: TEM) announced the introduction of xM for treatment response monitoring/TRM. This new liquid biopsy assay is designed to detect molecular responses to immune ...

A randomized trial of the addition of ruxolitinib to BCR::ABL1 tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia (CML) with molecular evidence of disease (SWOG trial S1712).

A retrospective analysis reveals that tyrosine kinase inhibitors offer a promising pathway for managing chronic myeloid leukemia in patients ages 75 and older, with increases in major molecular ...

With results from a head-to-head study comparing its newer chronic myeloid leukemia (CML) treatment Scemblix to its own standard-of-care tyrosine kinase inhibitor (TKI) Gleevec in newly diagnosed ...

Researchers evaluated the additional predictive value of molecular immune markers with the Predict Sepsis screening tools developed previously by the same research team.

HOUSTON -- An early molecular or cytogenetic response correlated with better long-term survival in heavily pretreated chronic-phase chronic myeloid leukemia (CML) treated with the BCR-ABL ...

Early response to ponatinib appeared predictive of survival among certain patients with chronic myeloid leukemia, according to findings presented at Society of Hematologic Oncology Annual Meeting ...

Doctors use molecular responses to monitor the effectiveness of CML treatment. A major molecular response is when the amount of the abnormal BCR – ABL gene in your blood and bone marrow is ...

Early results appear promising for frontline asciminib in patients with chronic phase chronic myeloid leukemia, according to researchers.

Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia PRESS RELEASE PR Newswire Dec. 11, 2021, 04:16 PM ...